866-997-4948(US-Canada Toll Free)

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Aug 2016

Category :

Pharmaceutical

No. of Pages : 442 Pages

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

Summary

Global Markets Directs, Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Renal Cell Carcinoma Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 11
Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 12
Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 13
Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Renal Cell Carcinoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Metastatic Renal Cell Carcinoma - Products under Development by Companies 22
Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 25
Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 26
Acceleron Pharma, Inc. 26
Amgen Inc. 27
Argos Therapeutics, Inc. 28
Astellas Pharma Inc. 29
Bayer AG 30
Bionomics Limited 31
Bionovis SA 32
Bristol-Myers Squibb Company 33
Cellceutix Corporation 34
Celldex Therapeutics, Inc. 35
Cerulean Pharma, Inc. 36
Dr. Reddy's Laboratories Limited 37
EirGenix Inc. 38
Eisai Co., Ltd. 39
Eli Lilly and Company 40
Exelixis, Inc. 41
Gene Techno Science Co., Ltd. 42
Genor BioPharma Co., Ltd. 43
Immune Design Corp. 44
Immunicum AB 45
Incyte Corporation 46
Mabion SA 47
MedImmune, LLC 48
Merck & Co., Inc. 49
Merck KGaA 50
Millennium Pharmaceuticals Inc 51
Mycenax Biotech Inc. 52
NewLink Genetics Corporation 53
Novartis AG 54
Oncobiologics, Inc. 55
Ono Pharmaceutical Co., Ltd. 56
Panacea Biotec Limited 57
Peloton Therapeutics, Inc. 58
Pfizer Inc. 59
Prima BioMed Ltd. 60
Rexahn Pharmaceuticals, Inc. 61
Richter Gedeon Nyrt. 62
Seattle Genetics, Inc. 63
Sevion Therapeutics, Inc. 64
Syndax Pharmaceuticals Inc 65
Taiwan Liposome Company, Ltd. 66
Tocagen Inc. 67
TVAX Biomedical, Inc. 68
Tyrogenex, Inc. 69
Metastatic Renal Cell Carcinoma - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 80
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 92
AGS-16C3F - Drug Profile 92
avelumab - Drug Profile 93
bevacizumab biosimilar - Drug Profile 98
bevacizumab biosimilar - Drug Profile 100
bevacizumab biosimilar - Drug Profile 101
bevacizumab biosimilar - Drug Profile 102
bevacizumab biosimilar - Drug Profile 103
bevacizumab biosimilar - Drug Profile 104
bevacizumab biosimilar - Drug Profile 105
bevacizumab biosimilar - Drug Profile 106
bevacizumab biosimilar - Drug Profile 107
bevacizumab biosimilar - Drug Profile 108
bevacizumab biosimilar - Drug Profile 109
BNC-105 - Drug Profile 110
cabozantinib s-malate - Drug Profile 115
capmatinib - Drug Profile 133
CDX-014 - Drug Profile 136
Cellular Immunotherapy for Metastatic Renal Cell Carcinoma - Drug Profile 137
Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 138
crizotinib - Drug Profile 139
CRLX-101 - Drug Profile 146
dalantercept - Drug Profile 157
durvalumab - Drug Profile 161
emibetuzumab - Drug Profile 171
entinostat - Drug Profile 173
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 180
G-305 - Drug Profile 187
IMP-321 - Drug Profile 189
INCAGN-1876 - Drug Profile 193
Intuvax - Drug Profile 195
ipilimumab - Drug Profile 201
KM-3174 - Drug Profile 209
lenvatinib mesylate - Drug Profile 220
LY-2510924 - Drug Profile 231
Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma - Drug Profile 233
nivolumab - Drug Profile 234
Orellanine - Drug Profile 262
panobinostat - Drug Profile 263
pazopanib hydrochloride + pembrolizumab - Drug Profile 271
pembrolizumab - Drug Profile 272
PT-2385 - Drug Profile 303
radium Ra 223 dichloride - Drug Profile 305
Recombinant Protein for Oncology - Drug Profile 314
rocapuldencel-T - Drug Profile 315
RX-0201 - Drug Profile 321
sapanisertib - Drug Profile 325
SGN-CD70A - Drug Profile 328
Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile 329
SNX-5422 - Drug Profile 330
SVN-002 - Drug Profile 332
TLC-388 - Drug Profile 333
trebananib - Drug Profile 335
TVI-Kidney-1 - Drug Profile 339
varlilumab - Drug Profile 340
X-82 - Drug Profile 346
Metastatic Renal Cell Carcinoma - Dormant Projects 349
Metastatic Renal Cell Carcinoma - Discontinued Products 354
Metastatic Renal Cell Carcinoma - Product Development Milestones 355
Featured News & Press Releases 355
Appendix 369
Methodology 369
Coverage 369
Secondary Research 369
Primary Research 369
Expert Panel Validation 369
Contact Us 369
Disclaimer 370

List of Tables
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016 15
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 18
Number of Products under Development by Companies, H2 2016 (Contd..1) 19
Number of Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Comparative Analysis by Late Stage Development, H2 2016 22
Comparative Analysis by Clinical Stage Development, H2 2016 23
Comparative Analysis by Early Stage Development, H2 2016 24
Comparative Analysis by Unknown Stage Development, H2 2016 25
Products under Development by Companies, H2 2016 26
Products under Development by Companies, H2 2016 (Contd..1) 27
Products under Development by Companies, H2 2016 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016 30
Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016 31
Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016 32
Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016 33
Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016 34
Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016 35
Metastatic Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016 36
Metastatic Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 37
Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016 38
Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 39
Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2016 40
Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 41
Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016 42
Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016 43
Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 44
Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016 45
Metastatic Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016 46
Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2016 47
Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016 48
Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016 49
Metastatic Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016 50
Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016 51
Metastatic Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2016 52
Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016 53
Metastatic Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016 54
Metastatic Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 55
Metastatic Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016 56
Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016 57
Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016 58
Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016 59
Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 60
Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016 61
Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016 62
Metastatic Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016 63
Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016 64
Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 65
Metastatic Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016 66
Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2016 67
Metastatic Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016 68
Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 69
Metastatic Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 70
Metastatic Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016 71
Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016 72
Metastatic Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016 73
Assessment by Monotherapy Products, H2 2016 74
Assessment by Combination Products, H2 2016 75
Number of Products by Stage and Target, H2 2016 77
Number of Products by Stage and Mechanism of Action, H2 2016 85
Number of Products by Stage and Route of Administration, H2 2016 92
Number of Products by Stage and Molecule Type, H2 2016 94
Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2016 351
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016 352
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016 353
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016 354
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016 355
Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2016 356

List of Figures
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016 15
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Comparative Analysis by Late Stage Development, H2 2016 22
Comparative Analysis by Clinical Stage Development, H2 2016 23
Comparative Analysis by Early Stage Products, H2 2016 24
Assessment by Monotherapy Products, H2 2016 74
Assessment by Combination Products, H2 2016 75
Number of Products by Top 10 Targets, H2 2016 76
Number of Products by Stage and Top 10 Targets, H2 2016 76
Number of Products by Top 10 Mechanism of Actions, H2 2016 84
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 84
Number of Products by Routes of Administration, H2 2016 91
Number of Products by Stage and Routes of Administration, H2 2016 91
Number of Products by Top 10 Molecule Types, H2 2016 93
Number of Products by Stage and Top 10 Molecule Types, H2 2016 93

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *